CHM 7.14% 1.5¢ chimeric therapeutics limited

Chimeric: Media Thread, page-695

  1. 78 Posts.
    lightbulb Created with Sketch. 32
    Potential suitor for CHM is BioNTech. They have USD21bn in the bank and have stated they want to build an oncology pipeline. Augurs well for leading cell therapy companies such as CHM l!
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.